Who Generates Higher Gross Profit? Genmab A/S or Alkermes plc

A Tale of Two Biopharma Giants: Genmab A/S vs. Alkermes plc

In the competitive world of biopharmaceuticals, financial performance is a key indicator of a company's success. Over the past decade, Genmab A/S and Alkermes plc have been at the forefront, each striving to maximize their gross profit. From 2014 to 2023, Genmab A/S consistently outperformed Alkermes plc, with a staggering 150% higher average gross profit. Notably, in 2023, Genmab A/S achieved a gross profit of approximately $16.25 billion, marking a 91% increase from 2022. In contrast, Alkermes plc's gross profit peaked at around $1.41 billion in 2023, reflecting a 58% growth from the previous year. This data highlights Genmab A/S's robust growth trajectory, driven by strategic innovations and market expansions. As the biopharma landscape evolves, these insights offer a glimpse into the financial dynamics shaping the industry's future.